Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1-20 of 936 trials

SPRING Rollover: Follow-Up Study

This study is for participants from the previous SPRING trial to assess ongoing effects and safety of the treatment. We aim to gather more information on its long-term benefits.

Non-Small Cell Lung Cancer6-12 monthsSafety phase (I)Efficacy phase (II)Oncology

Alzheimer's Disease and Down Syndrome: ACI-24.060 Study

We are testing a new treatment, ACI-24.060, to see if it is safe and can help generate an immune response in people with early Alzheimer's and adults with Down syndrome. This study will also look at its effects on brain amyloid levels.

Alzheimer's Disease>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Advanced Breast Cancer: RLY-2608 Treatment Study

We are testing a new treatment called RLY-2608 for individuals with advanced breast cancer and other solid tumors. This study aims to understand how safe and effective this treatment may be.

Advanced Solid Tumor with PIK3CA Mutation>2 yearsSafety phase (I)Oncology

Preventing Bronchopulmonary Dysplasia: New Treatment for Preterm Newborns

We are studying a new therapy using cell-derived vesicles to see if it can help prevent lung problems in extremely preterm newborns. This trial will assess both safety and effectiveness compared to a placebo.

Bronchopulmonary Dysplasia>2 yearsSafety phase (I)Efficacy phase (II)Investigational MedicinesPediatricsPulmonology

Chronic Lymphocytic Leukemia: Venetoclax and Epcoritamab Study

We are studying a combination of venetoclax and epcoritamab in patients with relapsed or refractory CLL or SLL. The goal is to see if this treatment improves disease control and overall survival compared to existing options.

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Peripheral T-Cell Lymphoma: Tolinapant with Decitabine/Cedazuridine

We are studying a new treatment combining tolinapant with oral decitabine/cedazuridine for patients with relapsed or refractory peripheral T-cell lymphoma. The goal is to assess safety and effectiveness compared to the current standard treatment.

T-cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Advanced Solid Tumors: M9140 Treatment Study

We are testing a new drug called M9140 for people with advanced solid tumors. The goal is to see if it can improve treatment outcomes compared to current therapies.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Diabetic Foot Ulcers: Phage Therapy Study

We are comparing standard treatment with phage therapy against standard treatment plus a placebo for diabetic foot ulcers infected by Staphylococcus aureus. This study aims to see if phage therapy can improve healing.

Diabetic Foot Ulcer1-2 yearsSafety phase (I)Efficacy phase (II)DiabetologyInfectious DiseasesInternal Medicine

Oligometastatic Solid Cancer: SBRT with ATRA Support

We are studying a new radiation therapy combined with a drug to support the immune system in patients with oligometastatic solid cancer. This trial aims to evaluate safety and how well the treatment works.

Oligometastatic Solid Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementOncology

Duchenne Muscular Dystrophy: SQY51 Treatment Study

We are studying the safety and effects of a new treatment called SQY51 in children and adults with Duchenne Muscular Dystrophy. The goal is to see how it impacts muscle function and overall well-being.

Duchenne Muscular Dystrophy1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOrthopedics and Traumatology

Multiple Myeloma: Anti-BCMA CAR T Cell Therapy

We are studying a new CAR T cell treatment for patients with relapsed or refractory Multiple Myeloma. The trial aims to evaluate its safety and effectiveness in improving patient outcomes.

Relapsed/Refractory Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Multiple Myeloma: KTX-1001 Treatment

We are testing different amounts of KTX-1001 to see if it is safe and tolerable for people with relapsed or treatment-resistant multiple myeloma.

Relapsed and Refractory Multiple Myeloma>2 yearsSafety phase (I)HematologyOncology

Prostate Cancer: Neoadjuvant Treatment with [177Lu]Lu-PSMA-617

We are studying a new method of delivering a targeted treatment for men with high-risk prostate cancer before surgery. The goal is to evaluate its safety and how well it works compared to standard approaches.

High-Risk Prostate Cancer3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology

Advanced Solid Tumors: TT125-802 Treatment Study

We are testing a new treatment for people with advanced solid tumors to see how safe it is and how well it works. This study will help us learn more about its effects in humans.

Advanced Solid Tumors1-2 yearsSafety phase (I)Oncology

Acyclovir Dosage for Obese Patients

We are exploring how to personalize acyclovir dosages for individuals with obesity. This study aims to improve treatment effectiveness and safety for this patient group.

ObesitySafety phase (I)Infectious DiseasesInternal Medicine

Acute Leukemia: 177Lu-PentixaTher Treatment

We are testing a new radioligand therapy for patients with relapsed or refractory CXCR4+ acute leukemia. The study aims to evaluate its effectiveness in treating this challenging condition.

Acute Leukemia>2 yearsSafety phase (I)Efficacy phase (II)HematologyOncology

Fanconi Anemia: Long-Term Study of RP-L102 Infusion

We are evaluating the long-term safety and health effects of a gene therapy infusion for patients with Fanconi Anemia. This study looks at blood health and potential risks over time.

Fanconi's AnemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost Reimbursement

Advanced Solid Tumors: ITF3756 Treatment Study

We are testing a new oral medication for patients with advanced solid tumors to see if it is safe and effective, both alone and with another treatment. This study aims to understand how well it works in combination with an anti-protein 4 agent.

Advanced Solid TumorsSafety phase (I)Oncology

Acute Myelogenous Leukemia: Siltuximab with Chemotherapy

We are testing a new combination of siltuximab with standard chemotherapy for patients with poor prognosis AML. The goal is to see if this approach improves treatment outcomes.

Acute Myeloblastic Leukemia (AML)>2 yearsSafety phase (I)HematologyOncology

Advanced Solid Tumors: REGN7075 with Cemiplimab

We are studying the safety and effectiveness of a new treatment combining REGN7075 and cemiplimab for patients with advanced cancers. This trial aims to explore how well this combination works and its impact on patients' quality of life.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology